alexa Biomarkers Journals| OMICS International |Brain-Disorders-Therapy

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Biomarkers

Until recently, Alzheimer’s disease (AD) was diagnosed clinically by excluding other conditions and pathologies, at best resulting in a diagnosis of probable AD . Compared to autopsy-confirmed diagnoses, only 68% of the dementia patients were correctly diagnosed using these clinical diagnostic criteria for AD . Moreover, a clinical diagnosis of probable AD was confined to the dementia stage of the disease, following several years of progressive cognitive deterioration and behavioral changes. The neuropathological brain lesions that consist of senile plaques and neurofibrillary tangles, start developing many years before the first symptoms of the disease appear. Until recently, Alzheimer’s disease (AD) was diagnosed clinically by excludingother conditions and pathologies, at best resulting in a diagnosis of probable AD . Compared to autopsy-confirmed diagnoses, only 68% of the dementia patients were correctly diagnosed using these clinical diagnostic criteria for AD . Moreover, a clinical diagnosis of probable AD was confined to the dementia stage of the disease, following several years of progressive cognitive deterioration and behavioral changes. The neuropathological brain lesions that consist of senile plaques and neurofibrillary tangles, start developing many years before the first symptoms of the disease appear. Sebastiaan Engelborghs, CSF Biomarkers for Alzheimer Disease Diagnosis: Recent and Future Perspectives
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2014

Top